ß 2- Adrenoceptors Are Critical for Antidepressant Treatment of Neuropathic Pain

Annals of Neurology

Volumn 65, Issue 2, 2009, Pages 218-225

  Yalcin, Ipek ^a   Choucair Jaafar, Nada ^a   Benbouzid, Malika ^a   Tessier, Luc Henri ^a   Muller, André ^b   Hein, Lutz ^c   Freund Mercier, Marie José ^a   Barrot, Michel ^a,d  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Hopitaux Universitaires de Strasbourg   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ALPRENOLOL; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ICI 118 551; METOPROLOL; NORTRIPTYLINE; PINDOLOL; POLYETHYLENE; PROPRANOLOL; SOTALOL; UNCLASSIFIED DRUG; YOHIMBINE; ADRENERGIC RECEPTOR AFFECTING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG WITHDRAWAL; EVENING DOSAGE; LOCOMOTION; MALE; MORNING DOSAGE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PAIN THRESHOLD; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SCIATIC NERVE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HYPERALGESIA; ISCHIALGIA; MOTOR ACTIVITY; MOUSE MUTANT; PAIN ASSESSMENT; PHYSIOLOGY; TIME;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DISEASE MODELS, ANIMAL; HYPERALGESIA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; PAIN MEASUREMENT; RECEPTORS, ADRENERGIC, BETA-2; SCIATICA; TIME FACTORS;

EID: 62549143968     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21542     Document Type: Article

References (39)

1. Merksey H, Bogdtik N. Classification of chronic pain. Seattle: IASP Press, 1994.
2. Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in posdierpetic neuralgia: a quantitative systematic review. PLoS Med 2005;2:cl64.
3. Attal N, Cruccu G, Haanpaii M, et al. EPNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006:13:1153-1169.
4. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12:13-21.
5. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-251.
6. Bouhassira D, Lantéri-Minet M, Attal N, et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136:380-387.
7. Berton O, Nestler EJ. New approaches to antidepressant drug discover: beyond monoamines. Nat Rev Neurosci 2006;7: 137-15P
8. Mosconi T, Krtiger L. Fixed-diameter polyethylene cuffs applied to the rat sciatic nerve induce a painful neuropathy: ul-trastructural morphometric analysis of axonal alterations. Pain 1996;64:37-57.
9. Pitcher GM, Ritchie J, Henry JL. Nerve constriction in the rat: model of neuropathic, surgical and central pain. Pain 1999:83: 37-46.
10. Cheng HY, Pitcher GM, Laviolette SR, et al. DREAM is a critical transcriptional repressor for pain modulation. Cell 2002; 108:31-43.
11. Coull JA, Beggs S, Boudreau D, et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuro pathic pain. Nature 2005;438:1017-1021.
12. Holdridge SV, Cahill CM. Spinal administration of a delta opioid receptor agonist attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Eur j Pain 2007;11: 685-693.
13. Benbouzid M, Pallage V, Rajalu M, et al. Sciatic nerve cuffing in mice: a model of sustained neuropathic pain. Eur J Pain 2008;12:591.....599.
14. Benbouzid M, Gavériaux-Ruff C, Yalciu I, et al. Delta-opi-oid receptors are critical for tricylic antidepressant treatment of neuropathic allodynia. Biol Psychiatry 2008;63: 633-636.
15. Benbouzid M, Choticair-Jaafar N, Yalcin I, et al. Chronic, but not acute, tricyclic antidepressant treatment alleviates neuropathic allodynia after sciatic nerve cuffing in mice. Eur J Pain 2008;12:1008-1017.
16. Chruscinski Aj, Rohrer DK, Schauble E, et al. Targeted disruption of the beta2 adrenergic receptor gene. J Biol Chem 1 999; 274:16694-16700.
17. Yalcin I, Aksu F, Belzung C. Effects of desipramine and tramadol in a chronic mild stress model in mice are altered by yohimbine but not by pindolol. Eur J Pharmacol 2005;514: 165-174.
18. Yalcin I, Aksu F, Bodard S, et al. Antidepressant-like effect of tramadol in the unpredictable chronic mild stress procedure: possible involvement of die noradrenergic system. Behav Pharmacol 2007;18:623.....631.
19. Introini-Collison I, Saghafi D, Novack GD, et al. Memory-enhancing effects of post-training dipivefrin and epinephrine: involvement of peripheral and central adrenergic receptors. Brain Res 1992;572:81-86.
20. Janitzky K, Linke R, Yilmazer-Hanke DM, et al. Disrupted visceral feedback reduces locomotor activity and influences background contextual fear conditioning in C57BL/6JO1aHsd mice. Behav Brain Res 2007;182:109-118.
21. Tornatzky W, Miczek KA. Behavioral and autonomic responses to intermittent social stress: differential protection by clonidine and metoprolol. Psychopharmacology 1994;116:346-356.
22. Fernandez-Guasti A, Lopez-Rubalcava C. Evidence for the involvement of the 5-HT1A receptor in the anxiety action of in-donrenafe and ipsapirone. Psychopharmacology 1990; 101: 354-358.
23. Guilloux JP, David DJ, Guiard BP, et al. Blockade of 5-HT1A receptors by (±)-pindolol potentiates cortical 5-HT outflow, but not antidepressant-like activity of paroxetine: microdialysis and behavioural approaches in 5-111 1A receptor knockout mice. Neuropsychopharmacology 2006;31: 2162-2172.
24. Lenard NR, Gettys TW, Dunn AJ. Activation of beta2- and beta3-adrenergic receptors increases brain tryptophan. J Pharmacol Exp Ther 2003;305:653-659.
25. Parale MP, Chakravarti S, Kulkarni SK. Evidence of beta-adrenergic involvement in forced swimming-induced behavioural despair of mice. Methods Find Exp Clin Pharmacol 1987;9:35-38.
26. Popik P, Kos T, Sowa-Kucma M, et al. Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology 2008;198:421-430.
27. Crassous PA, Denis C, Paris H, Sénard JM. Interest of alpha2-adrenergic agonists and antagonists in clinical practice: background, facts and perspectives. Curr Top Med Chem 2007;7:187-194.
28. Yoshimura M, Furue H. Mechanisms for the anti-nociceptive actions of the descending noradrenergic and serotonergic systems in die spinal cord. J Pharmacol Sci 2006;101:107-117.
29. Nicholson R, Dixon A, Spanswick D, Lee K. Noradrenergic receptor mRNA expression in adult rat superficial dorsal horn and dorsal root ganglion neurons. Neurosci Lett 2005;380:316-321.
30. Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron 2002;34:13-25.
31. Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003;38: 157-160.
32. Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in die treatment of neuropadiic pain. Basic Clin Pharmacol Toxicol 2005;96:399-409.
33. Mico JA, Ardid D, Berrocoso E, Eschalier A. Antidepressants and pain. Trends Pharmacol Sci 2006;27:348-354.
34. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053.
35. Chobanian AV, Bakris GL, Cushman WC, et al. The seventh report of the joint national committee on prevention, defection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560 -2572.
36. Silbersteiu SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002;22:491-512.
37. Dodick DW, Silbersteiu SD. Migraine prevention. Pract Neurol 2007;7:383-393.
38. Lee DA, Higginbithani EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm 2005;62:691-699.
39. Biondi B, Palmier! EA, Klain M, et al. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 2005:152:1-9.